Acute myelogenous leukemia: Successful treatment of relapse with cytosine arabinoside, VP 16ndash;213, vincristine and vinblastine (A-triple-V)
- 1 August 1982
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 18 (8) , 733-737
- https://doi.org/10.1016/0277-5379(82)90071-2
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Re-induction of complete remissions in adults with acute non-lymphocytic leukemiaLeukemia Research, 1981
- Treatment of Acute Myelogenous Leukemia in Children and AdultsNew England Journal of Medicine, 1980
- 4′-(9-Acridinylamino) Methanesulfon-m-Anisidide (AMSA): A New Drug Effective in the Treatment of Adult Acute LeukemiaAnnals of Internal Medicine, 1980
- TIMED SEQUENTIAL THERAPY OF HUMAN LEUKEMIA BASED UPON RESPONSE OF LEUKEMIC-CELLS TO HUMORAL GROWTH-FACTORS1977
- 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemiaBlood, 1976
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- 5-AZACYTIDINE (NSC 102816) - NEW DRUG FOR TREATMENT OF MYELOBLASTIC LEUKEMIA1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213Published by Elsevier ,1975
- Synchronization and recruitment in acute leukemiaJournal of Clinical Investigation, 1971